{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:08:52Z","timestamp":1794118132146,"version":"4.8.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Swim Across America, The Jenny Fund, A Shot for Life"},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DRG-2529-24"],"award-info":[{"award-number":["DRG-2529-24"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-024-00753-0","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T23:09:20Z","timestamp":1734563360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["CAR-T cell therapy for the treatment of adult high-grade gliomas"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-3114","authenticated-orcid":false,"given":"Sangwoo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"753_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"753_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"753_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100801","volume":"30","author":"ME Barish","year":"2022","unstructured":"Barish, M. E. et al. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. Neoplasia 30, 100801 (2022).","journal-title":"Neoplasia"},{"key":"753_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543\u20131550 (2015).","journal-title":"J. Clin. Oncol."},{"key":"753_CR5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","volume":"25","author":"S Stevanovi\u0107","year":"2019","unstructured":"Stevanovi\u0107, S. et al. A Phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin. Cancer Res. 25, 1486\u20131493 (2019).","journal-title":"Clin. Cancer Res."},{"key":"753_CR6","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"753_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"753_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"753_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942\u20138949 (2005).","journal-title":"J. Clin. Oncol."},{"key":"753_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"753_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"753_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"753_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/labinvest.3700233","volume":"85","author":"D Zagzag","year":"2005","unstructured":"Zagzag, D. et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab. Investig. 85, 328\u2013341 (2005).","journal-title":"Lab. Investig."},{"key":"753_CR16","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC Class I antigen presentation. Front. Immunol. 12, 636568 (2021).","journal-title":"Front. Immunol."},{"key":"753_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"753_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Rivi\u00e8re, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6 \/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"753_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"753_CR20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"753_CR21","doi-asserted-by":"publisher","first-page":"eabl3995","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao, Q. et al. Size-dependent activation of CAR-T cells. Sci. Immunol. 7, eabl3995 (2022).","journal-title":"Sci. Immunol."},{"key":"753_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203\u2013211 (2005).","journal-title":"J. Immunother."},{"key":"753_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165\u20131174 (2013).","journal-title":"Blood"},{"key":"753_CR24","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","volume":"180","author":"SE James","year":"2008","unstructured":"James, S. E. et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180, 7028\u20137038 (2008).","journal-title":"J. Immunol."},{"key":"753_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature11220","volume":"487","author":"JR James","year":"2012","unstructured":"James, J. R. & Vale, R. D. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 487, 64\u201369 (2012).","journal-title":"Nature"},{"key":"753_CR26","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","volume":"178","author":"AA Hombach","year":"2007","unstructured":"Hombach, A. A. et al. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J. Immunol. 178, 4650\u20134657 (2007).","journal-title":"J. Immunol."},{"key":"753_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125\u2013135 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"753_CR28","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 25, 2452\u20132465 (2017).","journal-title":"Mol. Ther."},{"key":"753_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"753_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells. Blood 124, 1070\u20131080 (2014).","journal-title":"Blood"},{"key":"753_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018). 96976.","journal-title":"JCI Insight"},{"key":"753_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933\u2013941 (2005).","journal-title":"Mol. Ther."},{"key":"753_CR33","doi-asserted-by":"publisher","first-page":"eaba7308","DOI":"10.1126\/scitranslmed.aba7308","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci. Transl. Med. 13, eaba7308 (2021).","journal-title":"Sci. Transl. Med."},{"key":"753_CR34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"753_CR35","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017\u20134023 (2015).","journal-title":"Blood"},{"key":"753_CR36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"DJ Green","year":"2018","unstructured":"Green, D. J. et al. Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood 132, 1011\u20131011 (2018).","journal-title":"Blood"},{"key":"753_CR37","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"753_CR38","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Investig. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Investig."},{"key":"753_CR39","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"753_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"753_CR41","doi-asserted-by":"publisher","first-page":"e23902","DOI":"10.1371\/journal.pone.0023902","volume":"6","author":"K Gabrusiewicz","year":"2011","unstructured":"Gabrusiewicz, K. et al. Characteristics of the alternative phenotype of microglia\/macrophages and its modulation in experimental gliomas. PLoS ONE 6, e23902 (2011).","journal-title":"PLoS ONE"},{"key":"753_CR42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/sj.onc.1210683","volume":"27","author":"A Wesolowska","year":"2008","unstructured":"Wesolowska, A. et al. Microglia-derived TGF-\u03b2 as an important regulator of glioblastoma invasion\u2014an inhibition of TGF-\u03b2-dependent effects by shRNA against human TGF-\u03b2 type II receptor. Oncogene 27, 918\u2013930 (2008).","journal-title":"Oncogene"},{"key":"753_CR43","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1227\/00006123-199512000-00016","volume":"37","author":"M Hishii","year":"1995","unstructured":"Hishii, M. et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37, 1160\u20131167 (1995).","journal-title":"Neurosurgery"},{"key":"753_CR44","doi-asserted-by":"publisher","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","volume":"17","author":"EK Nduom","year":"2015","unstructured":"Nduom, E. K., Weller, M. & Heimberger, A. B. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 17, vii9\u2013vii14 (2015).","journal-title":"Neuro Oncol."},{"key":"753_CR45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.stem.2009.08.018","volume":"5","author":"H Ikushima","year":"2009","unstructured":"Ikushima, H. et al. Autocrine TGF-\u03b2 signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-Box factors. Cell Stem Cell 5, 504\u2013514 (2009).","journal-title":"Cell Stem Cell"},{"key":"753_CR46","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.bcp.2012.11.005","volume":"85","author":"JV Joseph","year":"2013","unstructured":"Joseph, J. V., Balasubramaniyan, V., Walenkamp, A. & Kruyt, F. A. E. TGF-\u03b2 as a therapeutic target in high grade gliomas\u2014promises and challenges. Biochem. Pharmacol. 85, 478\u2013485 (2013).","journal-title":"Biochem. Pharmacol."},{"key":"753_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jneuroim.2010.04.003","volume":"225","author":"T Avril","year":"2010","unstructured":"Avril, T. et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J. Neuroimmunol. 225, 22\u201333 (2010).","journal-title":"J. Neuroimmunol."},{"key":"753_CR48","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","volume":"18","author":"DA Wainwright","year":"2012","unstructured":"Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110\u20136121 (2012).","journal-title":"Clin. Cancer Res."},{"key":"753_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-011-0858-3","volume":"122","author":"M Mittelbronn","year":"2011","unstructured":"Mittelbronn, M. et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol. 122, 353\u2013365 (2011).","journal-title":"Acta Neuropathol."},{"key":"753_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"753_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imm.12380","volume":"143","author":"V Kumar","year":"2014","unstructured":"Kumar, V. & Gabrilovich, D. I. Hypoxia\u2010inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143, 512\u2013519 (2014).","journal-title":"Immunology"},{"key":"753_CR52","first-page":"58","volume":"29","author":"PB Medawar","year":"1948","unstructured":"Medawar, P. B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29, 58\u201369 (1948).","journal-title":"Br. J. Exp. Pathol."},{"key":"753_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/0167-5699(94)90247-X","volume":"15","author":"Z Fabry","year":"1994","unstructured":"Fabry, Z., Raine, C. S. & Hart, M. N. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today 15, 218\u2013224 (1994).","journal-title":"Immunol. Today"},{"key":"753_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.154.2.347","volume":"154","author":"DN Hart","year":"1981","unstructured":"Hart, D. N. & Fabre, J. W. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154, 347\u2013361 (1981).","journal-title":"J. Exp. Med."},{"key":"753_CR55","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1750-3639.2009.00318.x","volume":"19","author":"BD Choi","year":"2009","unstructured":"Choi, B. D. et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 19, 713\u2013723 (2009).","journal-title":"Brain Pathol."},{"key":"753_CR56","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman, R. & Prat, A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 7, a020412 (2015).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"753_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.0.CO;2-F","volume":"78","author":"MS Balda","year":"2000","unstructured":"Balda, M. S., Flores-Maldonado, C., Cereijido, M. & Matter, K. Multiple domains of occludin are involved in the regulation of paracellular permeability. J. Cell. Biochem. 78, 85\u201396 (2000).","journal-title":"J. Cell. Biochem."},{"key":"753_CR58","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3389\/fimmu.2017.01181","volume":"8","author":"R Razpotnik","year":"2017","unstructured":"Razpotnik, R., Novak, N., \u010curin \u0160erbec, V. & Rajcevic, U. Targeting malignant brain tumors with antibodies. Front. Immunol. 8, 1181 (2017).","journal-title":"Front. Immunol."},{"key":"753_CR59","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau, R., S\u00f6rgel, F. & Eiffert, H. Penetration of drugs through the blood\u2013cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23, 858\u2013883 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"753_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1750-3639.1991.tb00646.x","volume":"1","author":"WF Hickey","year":"1991","unstructured":"Hickey, W. F. Migration of hematogenous cells through the blood\u2013brain barrier and the initiation of CNS inflammation. Brain Pathol. 1, 97\u2013105 (1991).","journal-title":"Brain Pathol."},{"key":"753_CR61","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","volume":"26","author":"B Engelhardt","year":"2005","unstructured":"Engelhardt, B. & Ransohoff, R. M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26, 485\u2013495 (2005).","journal-title":"Trends Immunol."},{"key":"753_CR62","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/0167-5699(94)90218-6","volume":"15","author":"T Owens","year":"1994","unstructured":"Owens, T., Renno, T., Taupin, V. & Krakowski, M. Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol. Today 15, 566\u2013571 (1994).","journal-title":"Immunol. Today"},{"key":"753_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0026-2862(91)90030-F","volume":"41","author":"AS Lossinsky","year":"1991","unstructured":"Lossinsky, A. S. et al. Mechanisms of inflammatory cell attachment in chronic relapsing experimental allergic encephalomyelitis: a scanning and high-voltage electron microscopic study of the injured mouse blood\u2013brain barrier. Microvasc. Res. 41, 299\u2013310 (1991).","journal-title":"Microvasc. Res."},{"key":"753_CR64","first-page":"39","volume":"70","author":"J Greenwood","year":"1994","unstructured":"Greenwood, J., Howes, R. & Lightman, S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab. Investig. 70, 39\u201352 (1994).","journal-title":"Lab. Investig."},{"key":"753_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00401-004-0928-x","volume":"109","author":"H Wolburg","year":"2005","unstructured":"Wolburg, H., Wolburg-Buchholz, K. & Engelhardt, B. Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol. 109, 181\u2013190 (2005).","journal-title":"Acta Neuropathol."},{"key":"753_CR66","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1083\/jcb.34.1.207","volume":"34","author":"TS Reese","year":"1967","unstructured":"Reese, T. S. & Karnovsky, M. J. Fine structural localization of a blood\u2013brain barrier to exogenous peroxidase. J. Cell Biol. 34, 207\u2013217 (1967).","journal-title":"J. Cell Biol."},{"key":"753_CR67","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1083\/jcb.40.3.648","volume":"40","author":"MW Brightman","year":"1969","unstructured":"Brightman, M. W. & Reese, T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40, 648\u2013677 (1969).","journal-title":"J. Cell Biol."},{"key":"753_CR68","unstructured":"Shaikh, S. & Shaikh, H. CART Cell Therapy Toxicity-StatPearls (StatPearls Publishing, Treasure Island, FL, 2023)."},{"key":"753_CR69","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue, J. M. et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 6, 6109\u20136119 (2022).","journal-title":"Blood Adv."},{"key":"753_CR70","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"753_CR71","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"753_CR72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"753_CR73","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"753_CR74","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"753_CR75","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"753_CR76","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"753_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"753_CR78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"753_CR79","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.smim.2020.101385","volume":"47","author":"T Nejo","year":"2020","unstructured":"Nejo, T., Yamamichi, A., Almeida, N. D., Goretsky, Y. E. & Okada, H. Tumor antigens in glioma. Semin. Immunol. 47, 101385 (2020).","journal-title":"Semin. Immunol."},{"key":"753_CR80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","volume":"14","author":"X Tang","year":"2019","unstructured":"Tang, X. et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol. Ther. Oncolytics 14, 279\u2013287 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"753_CR81","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.7150\/ijbs.41105","volume":"16","author":"S Yang","year":"2020","unstructured":"Yang, S., Wei, W. & Zhao, Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int. J. Biol. Sci. 16, 1767\u20131773 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"753_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1461304","volume":"7","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. OncoImmunology 7, e1461304 (2018).","journal-title":"OncoImmunology"},{"key":"753_CR83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama, D. et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine 47, 33\u201343 (2019).","journal-title":"EBioMedicine"},{"key":"753_CR84","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."},{"key":"753_CR85","first-page":"3140","volume":"55","author":"CJ Wikstrand","year":"1995","unstructured":"Wikstrand, C. J. et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140\u20133148 (1995).","journal-title":"Cancer Res."},{"key":"753_CR86","doi-asserted-by":"publisher","first-page":"viii20","DOI":"10.1093\/neuonc\/nou236","volume":"16","author":"KL Congdon","year":"2014","unstructured":"Congdon, K. L. et al. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 16, viii20\u201325 (2014). Suppl 8.","journal-title":"Neuro Oncol."},{"key":"753_CR87","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/neuonc\/nov319","volume":"18","author":"AH Thorne","year":"2016","unstructured":"Thorne, A. H., Zanca, C. & Furnari, F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. 18, 914\u2013918 (2016).","journal-title":"Neuro Oncol."},{"key":"753_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejphar.2017.05.064","volume":"810","author":"DA Chistiakov","year":"2017","unstructured":"Chistiakov, D. A., Chekhonin, I. V. & Chekhonin, V. P. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur. J. Pharm. 810, 70\u201382 (2017).","journal-title":"Eur. J. Pharm."},{"key":"753_CR89","first-page":"22","volume":"6","author":"BD Choi","year":"2017","unstructured":"Choi, B. D., O\u2019Rourke, D. M. & Maus, M. V. Engineering chimeric antigen receptor T cells to treat glioblastoma. J. Target Ther. Cancer 6, 22\u201325 (2017).","journal-title":"J. Target Ther. Cancer"},{"key":"753_CR90","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"753_CR91","doi-asserted-by":"publisher","first-page":"e26757","DOI":"10.4161\/onci.26757","volume":"2","author":"BD Choi","year":"2013","unstructured":"Choi, B. D., Gedeon, P. C., Sanchez-Perez, L., Bigner, D. D. & Sampson, J. H. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology 2, e26757 (2013).","journal-title":"Oncoimmunology"},{"key":"753_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","volume":"5","author":"A Schmidts","year":"2023","unstructured":"Schmidts, A. et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neuro-Oncol. Adv. 5, vdac185 (2023).","journal-title":"Neuro-Oncol. Adv."},{"key":"753_CR93","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1073\/pnas.1219817110","volume":"110","author":"BD Choi","year":"2013","unstructured":"Choi, B. D. et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc. Natl Acad. Sci. USA 110, 270\u2013275 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"753_CR94","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/2326-6066.CIR-13-0049","volume":"1","author":"BD Choi","year":"2013","unstructured":"Choi, B. D. et al. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol. Res. 1, 163\u2013167 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"753_CR95","doi-asserted-by":"publisher","unstructured":"Bagley, S. J. et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-023-00709-6 (2024).","DOI":"10.1038\/s43018-023-00709-6"},{"key":"753_CR96","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"753_CR97","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0092-8674(00)80500-0","volume":"90","author":"Eph Nomenclature Committee","year":"1997","unstructured":"Eph Nomenclature Committee Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90, 403\u2013404 (1997).","journal-title":"Cell"},{"key":"753_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.cb.10.110194.001343","volume":"10","author":"P van der Geer","year":"1994","unstructured":"van der Geer, P., Hunter, T. & Lindberg, R. A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Dev. Biol. 10, 251\u2013337 (1994).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"753_CR99","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1541-7786.MCR-05-0056","volume":"3","author":"J Wykosky","year":"2005","unstructured":"Wykosky, J., Gibo, D. M., Stanton, C. & Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541\u2013551 (2005).","journal-title":"Mol. Cancer Res."},{"key":"753_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694941","volume":"11","author":"Q Lin","year":"2021","unstructured":"Lin, Q. et al. First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front. Oncol. 11, 694941 (2021).","journal-title":"Front. Oncol."},{"key":"753_CR101","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha, B., Inal, C. & Owonikoko, T. K. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 10, 1000 (2020).","journal-title":"Front. Oncol."},{"key":"753_CR102","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","volume":"27","author":"G Golinelli","year":"2020","unstructured":"Golinelli, G. et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 27, 558\u2013570 (2020).","journal-title":"Cancer Gene Ther."},{"key":"753_CR103","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/156800910791054167","volume":"10","author":"F Navid","year":"2010","unstructured":"Navid, F., Santana, V. M. & Barfield, R. C. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets 10, 200\u2013209 (2010).","journal-title":"Curr. Cancer Drug Targets"},{"key":"753_CR104","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/biom9080311","volume":"9","author":"S Cavdarli","year":"2019","unstructured":"Cavdarli, S., Groux-Degroote, S. & Delannoy, P. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules 9, 311 (2019).","journal-title":"Biomolecules"},{"key":"753_CR105","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1471-4159.1980.tb04630.x","volume":"34","author":"TD Traylor","year":"1980","unstructured":"Traylor, T. D. & Hogan, E. L. Gangliosides of human cerebral astrocytomas. J. Neurochem. 34, 126\u2013131 (1980).","journal-title":"J. Neurochem."},{"key":"753_CR106","doi-asserted-by":"publisher","first-page":"24884","DOI":"10.18632\/oncotarget.4670","volume":"6","author":"M Prapa","year":"2015","unstructured":"Prapa, M. et al. A novel anti-GD2\/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget 6, 24884\u201324894 (2015).","journal-title":"Oncotarget"},{"key":"753_CR107","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med. 24, 572\u2013579 (2018).","journal-title":"Nat. Med."},{"key":"753_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma. Mol. Cancer 22, 3 (2023).","journal-title":"Mol. Cancer"},{"key":"753_CR109","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","volume":"16","author":"N Ahmed","year":"2010","unstructured":"Ahmed, N. et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16, 474\u2013485 (2010).","journal-title":"Clin. Cancer Res."},{"key":"753_CR110","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094\u20131101 (2017).","journal-title":"JAMA Oncol."},{"key":"753_CR111","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"753_CR112","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med 27, 1544\u20131552 (2021).","journal-title":"Nat. Med"},{"key":"753_CR113","doi-asserted-by":"publisher","first-page":"42997","DOI":"10.18632\/oncotarget.17792","volume":"8","author":"A Sattiraju","year":"2017","unstructured":"Sattiraju, A. et al. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget 8, 42997\u201343007 (2017).","journal-title":"Oncotarget"},{"key":"753_CR114","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown, C. E. et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062\u20134072 (2015).","journal-title":"Clin. Cancer Res."},{"key":"753_CR115","doi-asserted-by":"publisher","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-02875-1 (2024).","DOI":"10.1038\/s41591-024-02875-1"},{"key":"753_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.775194","volume":"8","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. CD44-mediated poor prognosis in glioma is associated with M2-polarization of tumor-associated macrophages and immunosuppression. Front. Surg. 8, 775194 (2021).","journal-title":"Front. Surg."},{"key":"753_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-67","volume":"5","author":"G Liu","year":"2006","unstructured":"Liu, G. et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).","journal-title":"Mol. Cancer"},{"key":"753_CR118","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.18632\/oncotarget.3365","volume":"6","author":"DV Brown","year":"2015","unstructured":"Brown, D. V. et al. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6, 6267\u20136280 (2015).","journal-title":"Oncotarget"},{"key":"753_CR119","doi-asserted-by":"publisher","first-page":"e0166280","DOI":"10.1371\/journal.pone.0166280","volume":"11","author":"A Drake","year":"2016","unstructured":"Drake, A. et al. Interleukins 7 and 15 maintain human T cell proliferative capacity through STAT5 signaling. PLoS ONE 11, e0166280 (2016).","journal-title":"PLoS ONE"},{"key":"753_CR120","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3390\/biomedicines10092174","volume":"10","author":"M Tompa","year":"2022","unstructured":"Tompa, M. et al. Epigenetic suppression of the IL-7 pathway in progressive glioblastoma. Biomedicines 10, 2174 (2022).","journal-title":"Biomedicines"},{"key":"753_CR121","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.18632\/oncotarget.3880","volume":"6","author":"J Jacobs","year":"2015","unstructured":"Jacobs, J. et al. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget 6, 13462\u201313475 (2015).","journal-title":"Oncotarget"},{"key":"753_CR122","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.bjc.6603222","volume":"95","author":"PJ Adam","year":"2006","unstructured":"Adam, P. J. et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br. J. Cancer 95, 298\u2013306 (2006).","journal-title":"Br. J. Cancer"},{"key":"753_CR123","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/ijc.30830","volume":"141","author":"H Ge","year":"2017","unstructured":"Ge, H. et al. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. Int. J. Cancer 141, 1434\u20131444 (2017).","journal-title":"Int. J. Cancer"},{"key":"753_CR124","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14728222.12.3.341","volume":"12","author":"IS Grewal","year":"2008","unstructured":"Grewal, I. S. CD70 as a therapeutic target in human malignancies. Expert Opin. Ther. Targets 12, 341\u2013351 (2008).","journal-title":"Expert Opin. Ther. Targets"},{"key":"753_CR125","doi-asserted-by":"publisher","first-page":"17411","DOI":"10.3390\/ijms151017411","volume":"15","author":"L Xiong","year":"2014","unstructured":"Xiong, L., Edwards, C. K. & Zhou, L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int. J. Mol. Sci. 15, 17411\u201317441 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"753_CR126","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.7150\/ijbs.60894","volume":"17","author":"X Bu","year":"2021","unstructured":"Bu, X. et al. CD147 confers temozolomide resistance of glioma cells via the regulation of \u03b2-TrCP\/Nrf2 pathway. Int. J. Biol. Sci. 17, 3013\u20133023 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"753_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/srep32804","volume":"6","author":"X Xin","year":"2016","unstructured":"Xin, X. et al. CD147\/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis. Sci. Rep. 6, 32804 (2016).","journal-title":"Sci. Rep."},{"key":"753_CR128","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11060-017-2499-4","volume":"134","author":"H Li","year":"2017","unstructured":"Li, H. et al. CD147 and glioma: a meta-analysis. J. Neurooncol. 134, 145\u2013156 (2017).","journal-title":"J. Neurooncol."},{"key":"753_CR129","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11060-013-1207-2","volume":"115","author":"M Yang","year":"2013","unstructured":"Yang, M. et al. Prognostic significance of CD147 in patients with glioblastoma. J. Neurooncol. 115, 19\u201326 (2013).","journal-title":"J. Neurooncol."},{"key":"753_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18444-2","volume":"11","author":"H Tseng","year":"2020","unstructured":"Tseng, H. et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat. Commun. 11, 4810 (2020).","journal-title":"Nat. Commun."},{"key":"753_CR131","first-page":"3010","volume":"11","author":"R Sincevi\u010di\u016bt\u0117","year":"2018","unstructured":"Sincevi\u010di\u016bt\u0117, R. et al. MMP2 is associated with glioma malignancy and patient outcome. Int. J. Clin. Exp. Pathol. 11, 3010\u20133018 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"753_CR132","doi-asserted-by":"publisher","first-page":"C361","DOI":"10.1152\/ajpcell.1993.264.2.C361","volume":"264","author":"JA DeBin","year":"1993","unstructured":"DeBin, J. A., Maggio, J. E. & Strichartz, G. R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am. J. Physiol. 264, C361\u2013369 (1993).","journal-title":"Am. J. Physiol."},{"key":"753_CR133","first-page":"4871","volume":"58","author":"L Soroceanu","year":"1998","unstructured":"Soroceanu, L., Gillespie, Y., Khazaeli, M. B. & Sontheimer, H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58, 4871\u20134879 (1998).","journal-title":"Cancer Res."},{"key":"753_CR134","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1074\/jbc.M205662200","volume":"278","author":"J Deshane","year":"2003","unstructured":"Deshane, J., Garner, C. C. & Sontheimer, H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 278, 4135\u20134144 (2003).","journal-title":"J. Biol. Chem."},{"key":"753_CR135","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/S1740925X06000044","volume":"2","author":"MB McFerrin","year":"2006","unstructured":"McFerrin, M. B. & Sontheimer, H. A role for ion channels in glioma cell invasion. Neuron Glia Biol. 2, 39\u201349 (2006).","journal-title":"Neuron Glia Biol."},{"key":"753_CR136","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2990.2006.00720.x","volume":"32","author":"L Tatenhorst","year":"2006","unstructured":"Tatenhorst, L., Rescher, U., Gerke, V. & Paulus, W. Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol. Appl. Neurobiol. 32, 271\u2013277 (2006).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"753_CR137","doi-asserted-by":"publisher","first-page":"e2286","DOI":"10.1097\/MD.0000000000002286","volume":"94","author":"F Xu","year":"2015","unstructured":"Xu, F., Liu, F., Zhao, H., An, G. & Feng, G. Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: a meta-analysis. Medicine (Baltimore) 94, e2286 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"753_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.821875","volume":"10","author":"M Bose","year":"2022","unstructured":"Bose, M. et al. Overexpression of MUC1 induces non-canonical TGF-\u03b2 signaling in pancreatic ductal adenocarcinoma. Front. Cell Dev. Biol. 10, 821875 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"753_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01899-8","volume":"21","author":"F Khodabakhsh","year":"2021","unstructured":"Khodabakhsh, F., Merikhian, P., Eisavand, M. R. & Farahmand, L. Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling. Cancer Cell Int. 21, 200 (2021).","journal-title":"Cancer Cell Int."},{"key":"753_CR140","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2006.08.019","volume":"126","author":"K Ohtsubo","year":"2006","unstructured":"Ohtsubo, K. & Marth, J. D. Glycosylation in cellular mechanisms of health and disease. Cell 126, 855\u2013867 (2006).","journal-title":"Cell"},{"key":"753_CR141","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10120-014-0454-z","volume":"19","author":"F Tamura","year":"2016","unstructured":"Tamura, F. et al. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer 19, 85\u201397 (2016).","journal-title":"Gastric Cancer"},{"key":"753_CR142","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.bbagen.2007.09.010","volume":"1780","author":"MA Tarp","year":"2008","unstructured":"Tarp, M. A. & Clausen, H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 1780, 546\u2013563 (2008).","journal-title":"Biochim. Biophys. Acta"},{"key":"753_CR143","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0925-4439(99)00055-1","volume":"1455","author":"J Taylor-Papadimitriou","year":"1999","unstructured":"Taylor-Papadimitriou, J., Burchell, J., Miles, D. W. & Dalziel, M. MUC1 and cancer. Biochim. Biophys. Acta 1455, 301\u2013313 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"753_CR144","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.6729450","volume":"224","author":"GF Springer","year":"1984","unstructured":"Springer, G. F. T and Tn, general carcinoma autoantigens. Science 224, 1198\u20131206 (1984).","journal-title":"Science"},{"key":"753_CR145","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1073\/pnas.1907921117","volume":"117","author":"SA Dusoswa","year":"2020","unstructured":"Dusoswa, S. A. et al. Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proc. Natl Acad. Sci. USA 117, 3693\u20133703 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"753_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106606","volume":"187","author":"F Tong","year":"2023","unstructured":"Tong, F. et al. MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. Pharm. Res. 187, 106606 (2023).","journal-title":"Pharm. Res."},{"key":"753_CR147","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12026-011-8214-1","volume":"50","author":"OJ Finn","year":"2011","unstructured":"Finn, O. J. et al. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol. Res. 50, 261\u2013268 (2011).","journal-title":"Immunol. Res."},{"key":"753_CR148","doi-asserted-by":"publisher","unstructured":"Park, S. et al. Immunoengineering can overcome the glycocalyx armour of cancer cells. Nat. Mater. https:\/\/doi.org\/10.1038\/s41563-024-01808-0 (2024).","DOI":"10.1038\/s41563-024-01808-0"},{"key":"753_CR149","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey","year":"2016","unstructured":"Posey, A. D. et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444\u20131454 (2016).","journal-title":"Immunity"},{"key":"753_CR150","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"753_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan, S. et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol. Cancer 18, 29 (2019).","journal-title":"Mol. Cancer"},{"key":"753_CR152","doi-asserted-by":"publisher","first-page":"12823","DOI":"10.1073\/pnas.1413933111","volume":"111","author":"CA Crane","year":"2014","unstructured":"Crane, C. A. et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl Acad. Sci. USA 111, 12823\u201312828 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"753_CR153","doi-asserted-by":"publisher","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","volume":"1","author":"S Curio","year":"2021","unstructured":"Curio, S., Jonsson, G. & Marinovi\u0107, S. A summary of current NKG2D-based CAR clinical trials. Immunother. Adv. 1, ltab018 (2021).","journal-title":"Immunother. Adv."},{"key":"753_CR154","doi-asserted-by":"publisher","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","volume":"110","author":"F Wei","year":"2013","unstructured":"Wei, F. et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl Acad. Sci. USA 110, E2480\u20132489 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"753_CR155","doi-asserted-by":"publisher","first-page":"42214","DOI":"10.18632\/oncotarget.15031","volume":"8","author":"DH Heiland","year":"2017","unstructured":"Heiland, D. H. et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget 8, 42214\u201342225 (2017).","journal-title":"Oncotarget"},{"key":"753_CR156","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial. JAMA Oncol. 6, 1003 (2020).","journal-title":"JAMA Oncol."},{"key":"753_CR157","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.abq6990","volume":"378","author":"DJ Irvine","year":"2022","unstructured":"Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853\u2013858 (2022).","journal-title":"Science"},{"key":"753_CR158","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139\u2013152 (2017).","journal-title":"Annu. Rev. Med."},{"key":"753_CR159","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e11 (2018).","journal-title":"Cell"},{"key":"753_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther.\u2014Nucleic Acids 2, e105 (2013).","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"753_CR161","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059\u20131070 (2012).","journal-title":"J. Clin. Immunol."},{"key":"753_CR162","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J. Clin. Investig. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Investig."},{"key":"753_CR163","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","volume":"185","author":"I Zhu","year":"2022","unstructured":"Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431\u20131443.e16 (2022).","journal-title":"Cell"},{"key":"753_CR164","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419\u2013432.e16 (2016).","journal-title":"Cell"},{"key":"753_CR165","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"753_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378 (2021).","journal-title":"Sci. Transl. Med."},{"key":"753_CR167","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"753_CR168","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503.e8 (2019).","journal-title":"Cancer Cell"},{"key":"753_CR169","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"753_CR170","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2021","unstructured":"Lanitis, E. et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J. Exp. Med. 218, e20192203 (2021).","journal-title":"J. Exp. Med."},{"key":"753_CR171","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"753_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J. Immunother. Cancer 7, 304 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"753_CR173","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients With glioblastoma. J. Immunother. 42, 126\u2013135 (2019).","journal-title":"J. Immunother."},{"key":"753_CR174","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown, C. E. et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro-Oncology 24, 1318\u20131330 (2022).","journal-title":"Neuro-Oncology"},{"key":"753_CR175","doi-asserted-by":"publisher","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med (2024) https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","DOI":"10.1038\/s41591-024-02893-z"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00753-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00753-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00753-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T01:03:05Z","timestamp":1734570185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00753-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":175,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00753-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.V.M. is an inventor on patents related to adoptive cell therapies held by Massachusetts General Hospital (some licensed to Promab) and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in 2SeventyBio, Century Therapeutics, Neximmune, Oncternal, and TCR2, and has served as a consultant for multiple companies involved in cell therapies. M.V.M. is a member of the Board of Directors of 2SeventyBio. B.D.C. is an inventor of patents and patent applications relating to T-cell engineering approaches.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}